Skip to main content

Table 1 Demographic and baseline characteristics

From: Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial

Characteristic Healthy volunteers Patients with T2DM
Placebo Volixibat Placebo Volixibat
(n = 12) 0.5 mg
(n = 10)
1 mg
(n = 9)
5 mg
(n = 9)
10 mg
(n = 9)
(n = 3) 10 mg
(n = 8)
Age, years 38.9 ± 15.58 (20–62) 28.2 ± 11.65 (19–54) 28.9 ± 10.86 (19–45) 30.2 ± 12.46 (19–54) 59.6 ± 4.72 (55–65) 67.7 ± 2.08 (66–70) 65.5 ± 3.38 (61–70)
BMI, kg/m2 23.82 ± 1.816 (21.6–27.4) 23.74 ± 3.301 (20.1–28.7) 24.10 ± 2.841 (20.2–28.9) 23.12 ± 3.423 (19.0–29.1) 22.79 ± 2.958 (18.7–28.8) 29.77 ± 1.914 (28.0–31.8) 29.49 ± 3.512 (24.4–34.8)
Female, n (%) 7 (58.3) 2 (20.0) 4 (44.4) 2 (22.2) 5 (55.6) 0 0
Race, n (%)
 Caucasian 11 (91.7) 9 (90.0) 7 (77.8) 7 (77.8) 9 (100.0) 3 (100.0) 7 (87.5)
 Other 1 (8.3) 1 (10.0) 2 (22.2) 2 (22.2) 0 0 1 (12.5)
  1. BMI body mass index, T2DM type 2 diabetes mellitus
  2. Values are mean ± standard deviation (range) unless otherwise stated; data are from the safety analysis set